World Diabetes Market Analysis, 2009-2023

Table of Contents

• 1.1 Crucial Details of the Diabetes Market Trajectory
  • 1.1.1 Visiongain Predicts the Diabetes Market will approach $64 billion by 2023
  • 1.1.2 Diabetes is Spreading at an Epidemic Rate: The Need for Pharmaceuticals is Growing
  • 1.1.3 Diabetes Care Works: The Market Will Expand Significantly
  • 1.1.4 Awareness, Advocacy, and Government Spending aimed at Diabetes are all Expanding
• 1.2 Aims, Scope and Format of the Report
• 1.3 Research Methodology

• 2.1 What is Diabetes Mellitus?
  • 2.1.1 Symptoms of Diabetes
  • 2.1.2 Type 1 Diabetes
  • 2.1.3 Type 2 Diabetes
  • 2.1.4 Gestational Diabetes
  • 2.1.5 Other types of Diabetes
  • 2.1.6 “Pre-Diabetes”: Impaired Glucose Tolerance (IGT) and Metabolic Syndrome
• 2.2 Health Consequences: Diabetes Can Cause Heart, Kidney, Eye, and Nerve Damage
• 2.3 Obesity: The Major Diabetes Risk Factor
• 2.4 Other Risk Factors: Age, Genetics, Race
• 2.5 Diagnosis: Guidelines are Subject to Change
• 2.6 Prevalence: By All Measures, Diabetes Rates are Rising Epidemically
• 2.7 The Economic Costs of Diabetes: $58 billion in the US, $41 billion in Africa
• 2.8 Treatments
  • 2.8.1 Insulin: A Central Therapeutic Product
    • 2.8.1.1 Crucial Insulin Characteristics: Onset, Peak, and Duration Modifications
    • 2.8.1.2 Invasive Insulin Delivery Methods: Injections, Pumps, Insulin Jets
    • 2.8.1.3 Moving Away from Injections? Alternative Delivery Methods Under Development, and Set to Revolutionize the Market
  • 2.8.2 Medications
  • 2.8.3 More Novel Therapies? A New Discovery about How Insulin Works May Lead to New Drugs
• 2.9 Diabetes Treatment Noncompliance Rates 25% to 90%

• 3.1 Market Forecast, 2008-2023
• 3.2 Leading Drugs
  • 3.2.1 Byetta: Potentially Revolutionary Blockbuster
  • 3.2.2 Oral Antidiabetics Forecast
  • 3.2.3 Actos
  • 3.2.4 Avandia: Unlikely to Survive past 2013
  • 3.2.5 Januvia
  • 3.2.6 Avandamet
  • 3.2.7 Human Insulin and Analogues Forecast
  • 3.2.8 Lantus
  • 3.2.9 Novorapid
  • 3.2.10 Humalog
  • 3.2.11 Novomix
  • 3.2.12 Actraphane HM
  • 3.2.13 Levemir
  • 3.2.14 Other Diabetes-related Drugs: Symlin Up and Kinedak Down
• 3.3 Alternative Delivery Methods: The Possibilities to Watch

• 4.1 Novo Nordisk
• 4.2 Takeda
• 4.3 Sanofi-aventis
• 4.4 Eli Lilly
• 4.5 Amylin
• 4.6 Pipeline Developments
  • 4.6.1 Liraglutide
  • 4.6.2 Other GLP-1 Analogues
  • 4.6.3 DPP-4 Inhibitors
  • 4.6.4 Biguanides
  • 4.6.5 New Therapy Class: Sodium-glucose cotransporter-2 (SGLT2) inhibitors
  • 4.6.6 Insulin Pipelines: Some New Insulins, but Mostly Focused On Delivery Methods
  • 4.6.7 Pipeline for a Cure?

• 5.1 United States
• 5.2 Europe
• 5.3 Japan
• 5.4 India: Becoming the Largest World Market?
• 5.5 China: Another Region to Watch Closely
• 5.6 The Rest of the World

• 6.1 Strengths: Diabetes is Increasing, and Diabetes Drugs Work
• 6.2 Weaknesses
• 6.3 Opportunities
• 6.4 Threats
• 6.4.1 The Most Significant Threat: Potential Changes in Drug Approval Guidelines
• 6.4.2 Other Significant Threats
• 6.5 Interview with Fred Levine, M.D., Ph.D. Professor, Burnham Institute for Medical Research; Director, Sanford Children' s Health Research Center
  • 6.5.1 On alternative delivery methods:
  • 6.5.2 On cardiovascular problems associated with oral antidiabetics
  • 6.5.3 On obesity and diabetes
  • 6.5.4 On Byetta
  • 6.5.5 On Stem Cell Therapy/Cure
• 6.6 Interview with Bjorn Tyrberg, PhD. Associate Professor at Burnham Institute for Medical Research, Diabetes and Obesity Research Center.
  • 6.6.1 On Diet and Diabetes
  • 6.6.2 On Byetta and liraglutide